Jefferies lowers its price target to $6 from $7 on Buy-rated ZIOPHARM Oncology ZIOP on a slightly wider loss for Q4.
Jefferies notes, "Slightly wider 4Q11 net loss of $13.2M (vs. our est. $11.4M net loss) on ~10% higher OpEx of $16.6M. Our estimated current cash of ~$154M including the
recent equity raise of $49M should be sufficient through 1H13."
ZIOP closed at $4.61 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in